With lots of ASX shares to choose from on the Australian market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are outlined below. Here’s why they are bullish on them:
ANZ Group Holdings Ltd (ASX: ANZ)
According to a note out of Citi, its analysts have retained their buy rating and $39.25 price target on this banking giant’s shares. Citi highlights that Judo Capital Holdings Ltd (ASX: JDO) recently downgraded its earnings guidance due to three specific exposures. The broker believes these exposures are a credit risk problem and not signs of a systemic issue. As a result, it isn’t worried about ANZ at this stage. However, it concedes that the economy is in a challenging place and there are macro headwinds that the big banks could face. Nevertheless, the broker likes ANZ due to its exposure to business banking, which it prefers to retail banking at present. The ANZ share price is trading at $35.11 on Monday.
Neuren Pharmaceuticals Ltd (ASX: NEU)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this biotechnology company’s shares with an improved price target of $23.50. This follows news that European regulators have reversed a negative recommendation on its Daybue product, which makes its approval quite likely now. Outside this, the broker estimates that the market is giving no value to Neuren’s NNZ-2591 product, which is under development. This could be a big mistake given how it estimates the product could be a multi-billion-dollar value asset if it succeeds in its Phase 3 trial. Trial results for NNZ-2591 are expected towards the end of 2027. The Neuren Pharmaceuticals share price is fetching $15.63 at the time of writing.
Qualitas Ltd (ASX: QAL)
Analysts at Macquarie have retained their outperform rating on this alternative asset manager’s shares with a trimmed price target of $3.95. According to the note, the broker was pleased to see Qualitas upgrade its margin guidance for long-term funds management EBITDA. It notes that this is being driven by benefits from an AI-enabled platform that should streamline the investment process. In addition, it has been pleased to see the company continues its long run of growing funds under management quicker than peers. It expects this to underpin strong earnings per share growth through to at least FY 2028. The Qualitas share price is trading at $3.01 this morning.
The post Leading brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Anz Group right now?
Before you buy Anz Group shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Anz Group wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why this ASX biotech stock is soaring 30% today
- Bell Potter says this ASX healthcare share could rise 93% (It’s not CSL)
- 5 things to watch on the ASX 200 on Monday
- Top brokers name 3 ASX shares to buy next week
- Here are the top 10 ASX 200 shares today
Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group and Qualitas. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.